$1.21
2.39% day before yesterday
Nasdaq, Jul 11, 10:00 pm CET
ISIN
US87166L1008
Symbol
SYBX
Sector
Industry

Synlogic Inc Stock price

$1.21
-0.01 0.79% 1M
-0.21 14.76% 6M
-0.19 13.54% YTD
-0.24 16.52% 1Y
-15.14 92.60% 3Y
-26.84 95.68% 5Y
-739.04 99.84% 10Y
-739.04 99.84% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.03 2.39%
ISIN
US87166L1008
Symbol
SYBX
Sector
Industry

Key metrics

Basic
Market capitalization
$14.2m
Enterprise Value
$-3.1m
Net debt
positive
Cash
$17.3m
Shares outstanding
11.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1,415.7 | -
EV/Sales
negative | -
EV/FCF
0.2
P/B
1.1
Financial Health
Equity Ratio
64.3%
Return on Equity
-183.2%
ROCE
-127.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$10.0k | $0.0
EBITDA
$-16.6m | -
EBIT
$-16.6m | $-6.2m
Net Income
$-23.0m | $-5.6m
Free Cash Flow
$-17.4m
Growth (TTM | estimate)
Revenue
-99.7% | -100.0%
EBITDA
65.1% | -
EBIT
66.4% | 60.6%
Net Income
68.5% | 76.0%
Free Cash Flow
62.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-207,937.5% | -
EBIT
-207,937.5%
Net
-288,025.0% | -
Free Cash Flow
-218,025.0%
More
EPS
$-1.9
FCF per Share
$-1.5
Short interest
0.7%
Employees
1
Rev per Employee
$10.0k
Show more

Is Synlogic Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Synlogic Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Synlogic Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Synlogic Inc forecast:

Hold
50%
Sell
50%

Financial data from Synlogic Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.01 0.01
100% 100%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.47 7.47
45% 45%
74,700%
- Research and Development Expense 9.90 9.90
75% 75%
99,000%
-17 -17
65% 65%
-166,400%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -17 -17
66% 66%
-166,350%
Net Profit -23 -23
69% 69%
-230,400%

In millions USD.

Don't miss a Thing! We will send you all news about Synlogic Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Synlogic, Inc. is a clinical-stage biopharmaceutical company. It engages in drug discovery and development of synthetic biotic medicines. The firm focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.

Head office United States
CEO Mary Dooley
Employees 1
Founded 2017
Website www.synlogictx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today